Treat Implant Loosening of Percutaneous Osseointegrated Prosthetic Limbs with Intermittent Parathyroid Hormone

Abstract

We aim to evaluate parathyroid hormone, an FDA-approved agent, as a candidate to prevent and reverse the failure of percutaneous osseointegrated prosthetic limbs (POPL) caused by implant loosening due to initial instability. We will also investigate the cellular origin and molecular mechanism of the formation of peri-implant fibrotic tissue. For this reporting period the major goal was to determine the role of CXCL12+/LEPR+ cells in and the therapeutic potential of iPTH for fibrotic osseointegration failure of a POPL implant. However, we were delayed by the initial difficulty in the breeding of Cxcl12-creER; Ai14 mice which required back-crossing the breeders with wildtype mice. We then did 5 experiments to demonstrated that the Cxcl12-creER; Ai14 mice, can only label some of the fibroblasts in our POPL model. We have started breeding mice of a recently developed Lepr-creER line. We have also noticed the lack of fibrosis phenotype in some mice. We are testing various implants to improve there producibility of this mouse model.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1190474

Entities

People

  • Xu Yang

Organizations

  • Hospital for Special Surgery

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Bone And Bones
  • Breeding
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Electronic Mail
  • Fibroblasts
  • Fibrosis
  • Health Services
  • Hormones
  • Hospitals
  • Information Operations
  • Maryland
  • Medical Personnel
  • Parathyroid Hormones
  • Professional Development
  • Prosthetics
  • Therapy

Fields of Study

  • Medicine

Readers

  • Immunology and Pathology
  • Marine Ecological Systems Migration
  • Molecular Biology and Genetics